M. Losso

发表

Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

A. Mocroft, O. Kirk, N. Chentsova, 2009, AIDS.

Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study

A. Mocroft, O. Kirk, J. González, 2021, BMC Infectious Diseases.

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.

A. Mocroft, O. Kirk, H. Furrer, 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Editorial 44.pmd

B. Gazzard, Z. Fox, P. Vernazza, 2005 .

A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

B. Gazzard, Z. Fox, M. Youle, 2005, Antiviral therapy.

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

T. Griffin, R. Dewar, J. Metcalf, 2017, Open forum infectious diseases.

Safety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population

M. B. Bouzas, D. Ferrante, C. Biscayart, 2022, Public Health in Practice.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

A. Mocroft, O. Kirk, C. Tural, 2005, The Journal of infectious diseases.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

JD Lundgren, N Clumeck, A. Mocroft, 2007, The Lancet.

Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

Z. Fox, J. Lundgren, P. Cahn, 2007, Basic & clinical pharmacology & toxicology.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio

D. Cooper, H. Teppler, S. Kerr, 2013, The Lancet.

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

J. Lundgren, J. Neaton, B. Grund, 2018, The lancet. HIV.

The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies

R. Dewar, J. Metcalf, R. Davey, 2013, PloS one.

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

D. Cooper, H. Teppler, S. Kerr, 2015, PloS one.

CD4+ count-guided interruption of antiretroviral treatment.

J Darbyshire, N Clumeck, J Hoy, 2006, The New England journal of medicine.

Prospective evaluation of in-house polymerase chain reaction for diagnosis of mycobacterial diseases in patients with HIV infection and lung infiltrates.

A. Schijman, C. Sáez, J. Smayevsky, 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.